Cereno Scientific: More runway, more opportunity - Edison
Bildkälla: Stockfoto

Cereno Scientific: More runway, more opportunity - Edison

Cereno Scientific has outlined a comprehensive financing package, comprising a proposed SEK400m rights issue and restructuring of its existing SEK175m Fenja debt, marking an important step towards addressing the funding overhang on its clinical programmes.

If fully subscribed, management expects the funds to extend financial headroom into Q128, beyond the planned completion of recruitment in the Phase IIb EPIMODE trial for CS1 by end-2027.

Two accompanying warrant series (TO6 and TO7) could generate a further SEK400m, potentially financing EPIMODE through its Q428 readout. While we note that the discounted issue and warrants imply substantial potential dilution, we view improved financing visibility as positive, reducing near-term execution risk and potentially strengthening Cereno’s partnering position.

The key consideration now will be successful subscription (expected in January 2027) and securing the subsequent capital required to progress clinical plans.
Börsvärldens nyhetsbrev